MID-TERM AND LONG-TERM OUTCOMES OF USING MAGMARIS BVS STENTS IN PATIENTS WITH ACUTE CORONARY EVENTS

Article Sidebar

PDF
Published: 2024-05-13

Main Article Content

Sanakulov J.M.
“Samarkand regional branch of the Republican Specialized Scientific and Practical Medical Center of Cardiology.”
Yuldashov N.P.
Center for the development of professional qualification of medical workers
Kholikulov S.SH.
Мultidisciplinary medical center “Sog`lom Hayot” Tashkent, Samarkand, Uzbekistan
Yuldashova Kh.
Center for the development of professional qualification of medical workers
Eshpulatov A.S.
Мultidisciplinary medical center “Sog`lom Hayot” Tashkent, Samarkand, Uzbekistan

Abstract

To investigate the mid-term and long-term outcomes of using the next-generation Magmaris BVS stents in patients with acute coronary syndrome (ACS).

Downloads

Download data is not yet available.

Article Details

Issue

Vol. 4 No. 5 (2024): International Bulletin of Medical Sciences and Clinical Research

Section

Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite

MID-TERM AND LONG-TERM OUTCOMES OF USING MAGMARIS BVS STENTS IN PATIENTS WITH ACUTE CORONARY EVENTS. (2024). International Bulletin of Medical Sciences and Clinical Research, 4(5), 35-43. https://researchcitations.com/index.php/ibmscr/article/view/4045

References

Campos CM, Muramatsu T, Iqbal J, Zhang YJ, Onuma Y, Garcia-Garcia HM, Haude M, Lemos PA, Warnack B, Serruys PW. 2013. Bioresorbable drug-eluting magnesium-alloy scaffold for treatment of coronary artery disease. Int J Mol. Sci 14:24492–24500.

BIOSOLVE-II first-in-man trial. Eur. Heart J. Haude M, Ince H, Kische S, Abizaid A, Tölg R, Alves Lemos P, van Mieghem NM, Verheye S, Birgelen C von, Christiansen EH, Barbato E, Garcia-Garcia HM, Waksman R. 2018. Safety and clinical performance of a drug eluting absorbable metal scaffold in the treatment of subjects with de novo lesions in native coronary arteries: Pooled 12-month outcomes of BIOSOLVE-II and BIOSOLVE-III. Catheter Cardiovasc Interv.

Haude M, Ince H, Kische S, Abizaid A, Tölg R, Alves Lemos P, van Mieghem NM, Verheye S, Birgelen C von, Christiansen EH, Wijns W, Garcia-Garcia HM, Waksman R. 2017. Sustained safety and clinical performance of a drug-eluting absorbable metal scaffold up to 24 months: Pooled outcomes of BIOSOLVE-II and BIOSOLVE-III. EuroIntervention.

Johan Bennett, Alfonso Ielasi, Jan Torzewski, Quentin de Hemptinne, Enrico Cerrato, Magdalena Lanocha, Stefano Galli, Manel Sabaté. The Resorbable Magnesium Scaffold Magmaris in Acute Coronary Syndrome: An Appraisal of Evidence and User Group Guidance. // Cardiovascular Revascularization Medicine. Vol.39, June 2022, P.106-113 // https://doi.org/10.1016/j.carrev.2021.09.012.

Valgimigli M, Campo G, Monti M, et al. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation 2012;125:2015–26.

Schulz-Schüpke S, Byrne RA, Ten Berg JM, et al. ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting. Eur Heart J 2015;36:1252–63.

Michael J. Lipinski, Ricardo O. Escarcega, Nevin C. Baker, Hadiya A. Benn, Michael A. Gaglia, Rebecca Torguson, and Ron Waksman. Scaffold Thrombosis After Percutaneous Coronary Intervention With ABSORB Bioresorbable Vascular Scaffold: A Systematic Review and Meta-Analysis. // J Am Coll Cardiol Intv. 2016 Jan, 9 (1) 12–24. doi/10.1016/j.jcin.2015.09.024.